Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Dye-doped silica nanoparticles: synthesis, surface chemistry and bioapplications

Fig. 6

(adapted from Phillips et al. (2014))

Bioimaging clinical trials in humans using C-dots. a, b Whole-body distribution and PK of 124I-cRGDY–PEG–C dots. a Maximum intensity projection PET images 2, 24, and 72 h after IV injection of 124I-cRGDY–PEG–C dots demonstrated probe activity in the bladder (*), heart (yellow arrow), and bowel (white arrowhead). b Decay-corrected percent injected dose per gramme (%ID/g) of urine and plasma collected around 30 min, 4 h, 24 h, and 72 h after injection determined by gamma counting. Regions of interest were drawn on major organs for each patient’s PET scans to derive standardised uptake values and %ID/g (n = 5 patients). Plasma clearance half-times, t1/2, 1 and t1/2, 2 were attributed to renal and hepatobiliary clearance, respectively. c Magnetic resonance, MR, axial and sagittal images of the brain showing a subcentimeter cystic focus (arrows) in the pituitary gland. d MRI–PET images showing localisation of the C-dots (red spot) in the lesion site. e PET–CT images showing the same localisation

Back to article page